Overview
Zafrens is a cutting-edge life sciences company based in San Diego, California, focused on transforming drug discovery utilizing AI-driven methodologies and a scalable experimental platform. The company’s technological innovations are centered around a universal workflow that isolates, images, and sequences various cell modalities, thereby compressing drug discovery timelines and opening unprecedented opportunities for scientific discoveries.
Headquarters:
5890 Pacific Center Blvd., Suite 200
San Diego, CA 92121
Website: [zafrens.com](https://www.zafrens.com/)
Contact Email: hello@zafrens.com
Financial Highlights
On December 11, 2024, Zafrens secured a substantial $23 million in Series A financing led by Prime Movers Lab. This financial backing supports the expansion and scaling of their revolutionary drug discovery platform, enabling more robust interactions with multi-modality research and development projects.
Technology and Innovations
Z-Screen Platform: A leap forward from traditional high-throughput screening, Zafrens’ Z-Screen technology replaces the standard 96-well plates with massively scalable 50,000 to 200,000 well formats, integrating mRNA sequencing to provide unprecedented resolution and scale. This innovation facilitates millions of daily experiments on a benchtop instrument, underpinned by nanofabrication advances. The technology maps molecular states to functional outcomes via processes like Active-seq and Active-Drug-seq, thus redefining the high-throughput drug discovery paradigm.
Applications
The company's workflow involves dual inputs—cells and beads—resulting in high-throughput paired longitudinal imaging and sequencing data. Zafrens effectively connects perturbations with phenotype and genotype at the single-cell resolution, making significant strides in areas such as small molecules, biologics, cell therapies, and gene therapies.
Leadership Team
- Swamy Vijayan: Founder and visionary leader, serial entrepreneur in biotech and pharma. [LinkedIn](https://www.linkedin.com/in/swamy71)
- Yi Zhang: Co-Founder & EVP of Engineering, seasoned systems engineer in bio-instrument development. [LinkedIn](https://www.linkedin.com/in/yi-zhang-77a0b313)
- Vikas Goel: Executive Director, Cancer Biology and Translational Research, renowned in cancer biology and drug discovery. [LinkedIn](https://www.linkedin.com/in/vikas-goel-5426892)
- Justin Briggs: Head of Corporate Development, with a background in corporate development and high-throughput technology. [LinkedIn](https://www.linkedin.com/in/briggsly)
- Martin Smrcina: Executive Director, Medicinal Chemistry, experienced organic/medicinal chemist with industrial expertise. [LinkedIn](https://www.linkedin.com/in/martin-smrcina-94a408150)
- Maina Ndungu: Patent Contributor in Perturbation Technologies, with patents related to assay technologies.
Strategic Goals and Vision
Zafrens strives to democratize drug discovery, integrating insights generated at the intersection of biology, chemistry, and engineering. The company aims to create scalable, interconnected solutions to drastically reduce drug development timelines and costs, enhancing therapeutic exploration at unprecedented speed and detail.
Competitor Profiling
Zafrens is positioned within a competitive niche in the biotechnology sector with an annual revenue of approximately $6.2 million and a workforce of 40 employees.
Key Competitors
1. CN Bio
- Industry: Organ-on-a-Chip Technology
- Headquarters: Cambridge, England
- Revenue: Approximately $10.5 million
- Employee Count: 64
- Key Offerings: Human drug discovery systems such as PhysioMimix®. Recently raised $21 million in a Series B funding round.
2. Arpeggio Biosciences
- Industry: Biotechnology
- Headquarters: Boulder, Colorado
- Platform: Transcriptomic sequencing platform mapping chemistry to network biology. Two drug programs addressing chronic disease drug resistance. Raised $17 million in Series A funding.
3. miRecule
- Industry: Biotechnology Research
- Headquarters: Gaithersburg, Maryland
- Platform: RNA-based therapies focusing on cancer and muscular dystrophy. Their DREAmiR™ platform uses genomic and patient data for targeted therapeutics. Partnered with Sanofi for antibody-RNA conjugate therapeutics.
4. Forcyte Biotechnologies
- Industry: Biotechnology
- Headquarters: Los Angeles, California
- Focus: Mechanobiology and small-molecule drug discovery targeting cellular mechanics. Their FLECS platform supports high-throughput screening for drug discovery, emphasizing phenotypic screening and disease modeling.
